

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **MicroPort CardioFlow Medtech Corporation**

**微创心通医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2160)**

### **GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of MicroPort CardioFlow Medtech Corporation (the “**Company**”) hereby announces that on January 19, 2022, the Company has resolved to grant share options (the “**Options**”) to eligible participants (the “**Grantees**”), who are employees of the Company and its subsidiaries, to subscribe for up to an aggregate of 15,576,616 ordinary shares of the Company of US\$0.000005 each (the “**Shares**”) in the capital of the Company pursuant to the share option scheme adopted by the Company on March 13, 2020, subject to the acceptance of the Grantees.

Details of the Options are as follows:

Date of Grant:	January 19, 2022 (the “ <b>Date of Grant</b> ”)
Exercise price of the Options granted:	HK\$3.754 per Share, representing the highest of (i) the closing price of HK\$3.62 per Share as stated in the daily quotations sheet issued by the Stock Exchange on the Date of Grant; (ii) the average closing price of HK\$3.754 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant; and (iii) the nominal value of a Share of US\$0.000005
Number of Options granted:	15,576,616 Options (each Option shall entitle the holder of the Option to subscribe for one Share)
Validity period of the Options:	Ten (10) years from the Date of Grant

Vesting period of the Options:

among the total Options:

1. 9,216,616 Options shall be vested in the following manners: half of the Options shall be vested on January 19, 2024, and the rest shall be vested in tranches on the last trading day of each month during the period from February 2024 to January 2026 (inclusive); and
2. 6,360,000 Options shall be vested in the following manners: 20% of the Options shall be vested twelve months after the Date of Grant, and additional 20% of the Options shall be vested on each anniversary of the vesting commencement date thereafter.

Among the Grantees, Mr. Chen Guoming and Ms. Yan Luying, both are executive Directors, were granted 1,209,992 and 391,499 Options with a validity period of 10 years respectively.

The grant of Share Options to the executive Directors have been approved by all the independent non-executive Directors of the Company pursuant to Rule 17.04(1) of the Listing Rules.

To the best knowledge and belief of the Board, save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company, nor an associate (as defined under the Listing Rules) of any of them.

By order of the Board  
**MicroPort CardioFlow Medtech Corporation**  
**Luo Qiyi**  
*Chairman*

Shanghai, PRC, January 19, 2022

*As of the date of this announcement, the executive Directors are Mr. Chen Guoming, Ms. Yan Luying and Mr. Wu Guojia, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.*